$8.60
1.15% yesterday
Nasdaq, Nov 25, 10:13 pm CET
ISIN
US3984384087
Symbol
GRFS
Sector
Industry

Grifols, S.A. Sponsored ADR Class B Stock price

$8.60
-0.13 1.49% 1M
+1.40 19.44% 6M
-2.96 25.61% YTD
-1.19 12.16% 1Y
-2.90 25.22% 3Y
-13.99 61.93% 5Y
-9.82 53.32% 10Y
Nasdaq, Closing price Mon, Nov 25 2024
-0.10 1.15%
ISIN
US3984384087
Symbol
GRFS
Sector
Industry

Key metrics

Market capitalization $2.21b
Enterprise Value $14.25b
P/E (TTM) P/E ratio 34.29
EV/Sales (TTM) EV/Sales 2.01
P/S ratio (TTM) P/S ratio 0.31
P/B ratio (TTM) P/B ratio 0.98
Revenue growth (TTM) Revenue growth 11.94%
Revenue (TTM) Revenue $7.11b
EBIT (operating result TTM) EBIT $928.01m
Free Cash Flow (TTM) Free Cash Flow $-1.36m
Cash position $719.79m
EPS (TTM) EPS $0.25
P/E forward 23.55
P/S forward 0.29
EV/Sales forward 1.88
Short interest 0.40%
Show more

Is Grifols, S.A. Sponsored ADR Class B a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,883 stocks worldwide.

Grifols, S.A. Sponsored ADR Class B Stock Analysis

Unlock Scores for Free

Analyst Opinions

4 Analysts have issued a Grifols, S.A. Sponsored ADR Class B forecast:

1x Buy
25%
2x Hold
50%
1x Sell
25%

Analyst Opinions

4 Analysts have issued a Grifols, S.A. Sponsored ADR Class B forecast:

Buy
25%
Hold
50%
Sell
25%

Financial data from Grifols, S.A. Sponsored ADR Class B

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '23
+/-
%
7,106 7,106
12% 12%
100%
- Direct Costs 4,402 4,402
6% 6%
62%
2,704 2,704
23% 23%
38%
- Selling and Administrative Expenses 876 876
20% 20%
12%
- Research and Development Expense 423 423
27% 27%
6%
1,406 1,406
23% 23%
20%
- Depreciation and Amortization 478 478
12% 12%
7%
EBIT (Operating Income) EBIT 928 928
30% 30%
13%
Net Profit 170 170
23% 23%
2%

In millions USD.

Don't miss a Thing! We will send you all news about Grifols, S.A. Sponsored ADR Class B directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Grifols, S.A. Sponsored ADR Class B Stock News

Negative
Reuters
7 days ago
Grifols said on Tuesday that Canadian investment fund Brookfield's potential 6.45 billion euro ($6.8 billion) offer significantly undervalued the Spanish drugmaker's prospects and long-term potential.
Negative
Reuters
7 days ago
An investigating magistrate at the Spanish High Court said on Tuesday it had opened an investigation into U.S.-based short seller Gotham City's actions that brought down the share price of Spanish pharmaceutical firm Grifols in January.
Neutral
Business Wire
7 days ago
NEW YORK--(BUSINESS WIRE)--Mason Capital Management LLC (“Mason”), a registered investment advisor to funds and accounts holding approximately 2.1% of Grifols S.A. (“Grifols” or the “Company”) (BME: GRF) (NASDAQ: GRFS) class A shares, today sent a letter to the Grifols Board of Directors (the “Board”). In the letter, Mason reiterated the Company's corporate governance deficiencies, which have i...
More Grifols, S.A. Sponsored ADR Class B News

Company Profile

Grifols SA engages in the production of plasma derivatives. It operates through the following segments: Bioscience, Hospital, Diagnostic, Bio Supplies, and Others. The Bioscience Segment includes all activities related with products deriving from human plasma for therapeutic use. The Hospital Segment comprises of all non-biological pharmaceutical products and medical supplies manufactured by group companies earmarked for hospital pharmacy. The Diagnostic Segment deals with the marketing of diagnostic testing equipment, reagents, and other equipment. The Bio Supplies segment consists of all transactions related to biological products for non-therapeutic use. The Others segment focuses on the rendering of manufacturing services to third party companies. The company was founded by José Antonio Grifols Roig on November 18, 1940 and is headquartered in Barcelona, Spain.

Head office Spain
CEO Nacho Abia
Employees 23,744
Founded 1940
Website www.grifols.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today